Physician profile
James Hunter
NPI 1336233113
$8,400.91
in general payments reported to CMS, 2019-2025
30 companies · $692 in 2025
The $692 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,350 · 2022: $2,247 · 2023: $2,012 · 2024: $2,100 · 2025: $692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,621 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,620.92 |
| Education | $182.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,428.46 | 2021-2025 | |
| Amgen INC. | $1,104.25 | 2021-2025 | Enbrel, Tavneos, Otezla |
| Novartis Pharmaceuticals Corporation | $723.49 | 2021-2024 | |
| Janssen Biotech, INC. | $693.49 | 2021-2024 | Tremfya, Simponi Aria |
| Pfizer INC. | $665.17 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $481.35 | 2022-2025 | Saphnelo |
| Janssen Scientific Affairs, LLC | $317.21 | 2021-2022 | |
| Horizon Therapeutics Plc | $313.98 | 2021-2023 | Krystexxa |
| Lilly USA, LLC | $306.78 | 2021-2024 | Taltz |
| Radius Health, INC. | $291.30 | 2021-2025 | Tymlos |
| Ucb, INC. | $284.60 | 2023-2025 | Cimzia, Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $230.58 | 2021-2025 | Orencia |
| Genzyme Corporation | $207.08 | 2021-2024 | |
| Glaxosmithkline, LLC. | $201.68 | 2022-2025 | Benlysta, Nucala |
| Aurinia Pharma U.S., INC. | $150.31 | 2021-2024 | Lupkynis |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $144.87 | 2025 | |
| Alexion Pharmaceuticals, INC. | $130.76 | 2021-2024 | Strensiq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.33 | 2021-2024 | Ofev, Cyltezo |
| Sobi, INC | $107.08 | 2023-2024 | |
| Organon LLC | $93.43 | 2022-2025 | Renflexis, Hadlima |
| Genentech USA, INC. | $66.18 | 2021-2023 | Actemra |
| Mallinckrodt Hospital Products INC. | $62.39 | 2021 | |
| Sandoz INC. | $57.31 | 2023-2024 | Hyrimoz |
| Sanofi-Aventis U.S. LLC | $54.99 | 2024 | |
| Kiniksa Pharmaceuticals, Ltd. | $53.49 | 2022-2023 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $38.13 | 2021-2025 | Opsumit, Uptravi |
| Ani Pharmaceuticals, INC. | $21.38 | 2025 | Purified Cortrophin Gel |
| Kiniksa Pharmaceuticals International, Plc | $21.33 | 2024 | Arcalyst |
| Ultragenyx Pharmaceutical INC. | $20.40 | 2022 | |
| Fresenius Kabi USA, LLC | $17.11 | 2024 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hunter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.